Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
“A fascinating case report on Factor VIII Aurora – the first ever natural gain-of-function mutation in Factor VIII!
This groundbreaking discovery from Aurora, Colorado reveals a novel mutation (p.Arg590Ser) that dramatically increases Factor VIII activity to 300-900% of normal and causes severe resistance to protein C regulation.
Just as Factor IX Padua revolutionised haemophilia B treatment, this natural ‘supercharged’ Factor VIII variant could transform future gene therapy approaches for haemophilia A.
The case highlights the importance of thorough investigation in young patients with unexplained thrombosis – sometimes the most puzzling cases lead to the most significant breakthroughs!”
Check here for more.
Read the full case here.
More insights on Hemostasis Today.
-
Sep 13, 2025, 10:49Ranjeet Ajmani Invites You To Join The AABB-AATM Joint Webinar on Plasma Fractionation
-
Sep 13, 2025, 10:23Peter Lenting at BIC 2025: Fantastic Lecture on FVIII Mimetics
-
Sep 13, 2025, 09:54Cihan Ay: ISTH 2026 In Planning!
-
Sep 12, 2025, 06:39Chokri Ben Lamine: Approach to Intra-Operative Bleeding in G6P Deficiency – Key Causes and Management
-
Sep 12, 2025, 05:33Rafael Gomes Highlights Key ESC 2025 CABG Findings: Aspirin Monotherapy Still Best After Surgery
-
Sep 14, 2025, 04:16F8 Gene Variants Affect Desmopressin Response in Female Hemophilia A Carriers
-
Sep 13, 2025, 10:36Drug-Induced Immune Haemolytic Anaemia: A Decade Review by Abdul Mannan
-
Sep 13, 2025, 09:44Christelle Orlando: Type II Antithrombin Deficiency Frequently Underdiagnosed Due to Assay Limitations
-
Sep 13, 2025, 07:18Eric Topol Shares a Study on The Consequences of Our Pervasive Exposure to Micro- and Nanoplastics
-
Sep 13, 2025, 06:30Steven Grover on The Role of FXII in the Pathogenesis of VTE
-
Sep 12, 2025, 15:21Christian Schäfer: INR Self-Management Has Officially Been Given Class IA Status in the ESC Guidelines
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 14, 2025, 06:39Abdul Mannan on Factor VIII Aurora: First Natural Gain-of-Function Mutation in Haemophilia A
-
Sep 13, 2025, 13:34Brian O Mahony on 5-Year Roctavian Gene Therapy Data from BIC2025
-
Sep 13, 2025, 10:55José Antonio García Erce: Platelet Program for the Management of the Patient's Blood
-
Sep 13, 2025, 06:49Emna Gouider Belhadjali on the Role of NMOs in Advocating for Equitable Access to Diagnosis for WGBDs
-
Sep 12, 2025, 09:30Arun V J Explains How Blood Donation Rules Differ Worldwide and Why Your Donation Saves Lives Everywhere